Automation in Biopharma Industry Market Report 2026

The automation in biopharma industry market size has grown strongly in recent years. It will grow from $2.19 billion in 2025 to $2.35 billion in 2026 at a compound annual growth rate (CAGR) of 7.1%. The growth in the historic period can be attributed to increasing complexity of biologic drug production, rising demand for scalable biopharma manufacturing, early adoption of laboratory automation, expansion of contract manufacturing services, advancements in process control technologies.

The automation in biopharma industry market size is expected to see strong growth in the next few years. It will grow to $3.16 billion in 2030 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to increasing investments in smart biomanufacturing facilities, growing adoption of continuous manufacturing, expansion of personalized biologics production, rising demand for regulatory-compliant automation, increasing focus on manufacturing efficiency optimization. Major trends in the forecast period include increasing adoption of robotic manufacturing platforms, rising integration of digital twin technologies, growing use of automated quality control systems, expansion of end-to-end bioprocess automation, enhanced focus on data-driven manufacturing.

The rising adoption of robots in pharmaceutical manufacturing is expected to drive the growth of automation in the biopharma industry market. Robots in pharmaceutical manufacturing refer to advanced automated systems and machines that carry out various tasks involved in the production and packaging of pharmaceutical products. These robots are widely applied across multiple areas in pharmaceutical manufacturing, including secondary packaging, intralogistics, laboratory automation, pick and place operations, pharmacy process automation, and personalized medicine, leading to increased productivity, enhanced accuracy, minimized contamination risk, and improved worker safety. For example, in September 2024, according to the International Federation of Robotics, a Germany-based professional non-profit organization, industrial robot installations in the manufacturing sector in Europe grew by 9%, reaching a record total of 92,393 units. Of these, 80% were installed within the European Union, amounting to 73,534 units, marking a 2% increase from the previous year. Hence, the growing use of robots in pharmaceutical manufacturing is anticipated to propel the expansion of automation in the biopharma industry market.

Major companies in the biopharma industry are implementing automation solutions, concentrating on technological innovations such as robotic cell-therapy manufacturing platforms for scalable, efficient, and low-error production of advanced therapies. A robotic cell-therapy manufacturing platform integrates mobile robotics, aseptic fluid-handling systems, automated tube welding, and digital process control into a fully closed and modular system, replacing traditional manual bioprocessing that depends heavily on labor and open systems. For example, in May 2023, Cellular Origins, a UK-based life sciences automation company, introduced Constellation, a configurable robotic platform for advanced therapy manufacturing. The platform combines autonomous mobile robots, sterile fluid-transfer technology, and modular processing consoles, enabling seamless integration with existing bioprocessing workflows. It enhances space efficiency by 30 times, reduces labor requirements by 16-fold, and lowers production costs by 51%, while providing complete digital interconnection for quality control and remote monitoring.

In January 2024, Bruker Corporation, a US-based provider of high-performance scientific instruments and analytical systems, acquired Chemspeed Technologies AG for an undisclosed amount. Through this acquisition, Bruker intends to accelerate the digital transformation of R&D and quality control laboratories in the biopharma and life sciences sectors by incorporating Chemspeed’s modular automated laboratory and robotics workflow solutions. Chemspeed Technologies AG is a Switzerland-based company that offers modular automation and robotics workstations for laboratory R&D and quality control workflows.

Major companies operating in the automation in biopharma industry market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Danaher Corporation, ABB Ltd, Siemens Healthineers AG, Emerson Electric Co., Becton Dickinson and Company (BD), Corning Incorporated, Rockwell Automation Inc., Agilent Technologies Inc., PerkinElmer Inc., Sartorius AG, bioMérieux SA, Mettler-Toledo International Inc., Beckman Coulter Inc., Waters Corporation, Pall Corporation, Bruker Corporation, Qiagen N.V., Eppendorf AG, Tecan Group Ltd., Promega Corporation, Brooks Automation Inc., Omron Automation, Hamilton Company, Integra Biosciences AG, Gilson Inc., Analytik Jena AG, BioTek Instruments Inc.

North America was the largest region in the automation in biopharma industry market in 2025. The regions covered in the automation in biopharma industry market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the automation in biopharma industry market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the automation in biopharma industry market by increasing costs of imported automation hardware, robotics, sensors, control systems, and specialized software platforms. Biopharmaceutical manufacturers in North America and Europe are most affected due to dependence on imported automation technologies, while Asia-Pacific faces cost pressure on facility expansion projects. These tariffs are raising capital investment requirements and slowing automation rollouts. At the same time, they are encouraging domestic production of automation equipment, regional software development, and localized system integration capabilities.

The automation in biopharma industry market research report is one of a series of new reports that provides automation in biopharma industry market statistics, including automation in biopharma industry industry global market size, regional shares, competitors with a automation in biopharma industry market share, detailed automation in biopharma industry market segments, market trends and opportunities, and any further data you may need to thrive in the automation in biopharma industry industry. This automation in biopharma industry market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Automation in the biopharma industry involves the incorporation of advanced technologies and robotics into different phases of the biopharmaceutical manufacturing process. It encompasses the use of automated systems and equipment to perform tasks that were traditionally done by humans, aiming to enhance efficiency, precision, and productivity in the production of biopharmaceutical products.

The primary technologies in automation within the biopharma industry are automation technology and digitization technology. Automation technology involves the use of various tools, including robotics, artificial intelligence (AI), and software systems, to automate and optimize processes and tasks that were previously carried out by humans. It encompasses elements such as automation hardware, automation software, service project phases, and service operation phases, which are applied across clinical phases, drug discovery phases, and production phases.

The automation in biopharma industry market consists of revenues earned by entities by providing high-throughput screening, sample management, and cell culture automation used during the process. The market value includes the value of related goods sold by the service provider or included within the service offering. The automation in biopharma industry market also includes sales of automated dissolution testing systems, robotic sample storage and retrieval systems, and chromatography systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.